NetScientific
NetScientific is a venture capital firm based in London, United Kingdom, founded in 2008. The company specializes in seed, early, and mid-stage investments, focusing on transformative biomedical and healthcare technologies, particularly in digital health, diagnostics, and therapeutics. NetScientific targets companies that significantly enhance the health and well-being of individuals with chronic diseases. Its investment strategy emphasizes sustainability and technology, with interests in data analytics, wearable technologies, and devices. The firm typically invests up to £15 million but may consider larger sums, preferring to maintain a controlling interest in its principal subsidiaries. NetScientific differentiates itself through a capital-light investment approach, employing its balance sheet judiciously while also utilizing its wholly owned venture capital subsidiary for syndicating investments. The company manages an international portfolio of innovative life science and technology firms, seeking to drive growth and deliver returns through strategic management and liquidity events.
Top Stages
14 past transactions
Vortex Biosciences
Venture Round in 2023
Vortex Biosciences, Inc., established in 2010 and headquartered in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company integrates cancer biology, microfluidic engineering, and informatics to deliver advanced tools for isolating and characterizing circulating tumor cells (CTCs). Vortex's flagship product is the VTX-1 Liquid Biopsy System, which automates the label-free isolation and collection of viable CTCs directly from whole blood, enabling healthcare institutions and professionals to make informed therapeutic decisions efficiently.
Sofant
Venture Round in 2022
Sofant Technologies Ltd, established in 2011 and headquartered in Edinburgh, UK, specializes in designing and licensing fabless smart antenna and tunable RF solutions for smartphone and tablet manufacturers. The company's core expertise lies in antenna and RF micro-electro-mechanical systems (MEMS) solutions, offering products such as compact smart antenna solutions, tunable impedance matching modules, and RF MEMS capacitors and phase shifters. Sofant's innovative, low-cost RF MEMS technology aims to address power consumption and heat issues in high-frequency phased array antenna systems, making it a key player in the emerging millimeter-wave market for 5G and SatCom applications.
Vortex Biosciences
Debt Financing in 2022
Vortex Biosciences, Inc., established in 2010 and headquartered in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company integrates cancer biology, microfluidic engineering, and informatics to deliver advanced tools for isolating and characterizing circulating tumor cells (CTCs). Vortex's flagship product is the VTX-1 Liquid Biopsy System, which automates the label-free isolation and collection of viable CTCs directly from whole blood, enabling healthcare institutions and professionals to make informed therapeutic decisions efficiently.
Q-Bot
Venture Round in 2022
Q-Bot Limited, established in 2012 and headquartered in London, UK, specializes in the manufacture of robotic tools designed to move beneath floors, applying insulation to floorboards. This innovative solution aims to improve building energy efficiency while minimizing disruption during installation. The company's robotics platform has broader applications across various industries, supported by a combination of government grants, private investments, and sales revenue. Notable backers include Climate-KIC, The Technology Strategy Board, and The Department for Energy and Climate Change.
Vortex Biosciences
Corporate Round in 2022
Vortex Biosciences, Inc., established in 2010 and headquartered in Palo Alto, California, specializes in developing liquid biopsy technology for cancer diagnosis and monitoring. The company integrates cancer biology, microfluidic engineering, and informatics to deliver advanced tools for isolating and characterizing circulating tumor cells (CTCs). Vortex's flagship product is the VTX-1 Liquid Biopsy System, which automates the label-free isolation and collection of viable CTCs directly from whole blood, enabling healthcare institutions and professionals to make informed therapeutic decisions efficiently.
Q-Bot
Venture Round in 2021
Q-Bot Limited, established in 2012 and headquartered in London, UK, specializes in the manufacture of robotic tools designed to move beneath floors, applying insulation to floorboards. This innovative solution aims to improve building energy efficiency while minimizing disruption during installation. The company's robotics platform has broader applications across various industries, supported by a combination of government grants, private investments, and sales revenue. Notable backers include Climate-KIC, The Technology Strategy Board, and The Department for Energy and Climate Change.
EpiBone
Venture Round in 2021
EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, that specializes in developing advanced bone and cartilage reconstruction solutions. Founded in 2013, EpiBone leverages innovative techniques involving patient-specific bone scans and the use of the patient's own stem cells to create autologous-like bone grafts. These grafts are cultivated in custom bioreactors, promoting efficient bone formation and regeneration. EpiBone's lead product, an anatomically precise living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023, while the company is also developing a cartilage repair portfolio that includes an allogeneic osteochondral plug and an injectable cartilage filler. This pioneering work positions EpiBone at the forefront of regenerative medicine, aiming to transform orthopedic repair and improve patient outcomes through a streamlined surgical approach and reduced recovery times.
Sofant
Venture Round in 2021
Sofant Technologies Ltd, established in 2011 and headquartered in Edinburgh, UK, specializes in designing and licensing fabless smart antenna and tunable RF solutions for smartphone and tablet manufacturers. The company's core expertise lies in antenna and RF micro-electro-mechanical systems (MEMS) solutions, offering products such as compact smart antenna solutions, tunable impedance matching modules, and RF MEMS capacitors and phase shifters. Sofant's innovative, low-cost RF MEMS technology aims to address power consumption and heat issues in high-frequency phased array antenna systems, making it a key player in the emerging millimeter-wave market for 5G and SatCom applications.
PointGrab
Venture Round in 2021
PointGrab Ltd. is a technology company based in Hod Hasharon, Israel, specializing in machine learning solutions for optical Internet of Things (IoT) devices aimed at home and building automation. Founded in 2008, PointGrab develops advanced optical sensors that integrate with connected lighting fixtures and other building systems to enhance the management of commercial real estate. Its flagship product, PointSwitch, utilizes machine learning algorithms to provide various functionalities, including occupancy sensing, ambient light sensing, and behavior analytics of occupants. This technology allows organizations to optimize their real estate efficiency while ensuring employee privacy and welfare, positioning PointGrab as a leader in smart building solutions.
SageTech Medical
Seed Round in 2021
SageTech Medical Equipment is a company that specializes in developing innovative anesthetic technologies for both human and veterinary healthcare providers. Founded in 2015 and headquartered in Paignton, United Kingdom, the company has created a patent-pending process that captures, extracts, and purifies inhalational anesthetic agents. This technology aims to reduce both the financial and environmental costs associated with anesthesia, promoting a circular economy for anesthetic gases that were previously considered waste. SageTech's solutions include large-scale systems for industrial applications as well as compact, integrated systems designed for use within anesthetic machines, allowing for efficient recycling of volatile anesthetic emissions to meet strict pharmaceutical standards.
ProAxsis
Acquisition in 2020
ProAxsis Ltd. is a biotechnology company that focuses on developing laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers associated with various diseases. The company's innovative tests utilize patented ProteaseTags®, which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. ProAxsis has validated several active protease species as biomarkers of disease activity in conditions such as cancer, infections, and respiratory diseases, including bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). In 2016, the company registered its first immunoassay for the specific measurement of active neutrophil elastase, a significant biomarker for lung infection and inflammation, with a European CE Mark, highlighting its commitment to advancing medical diagnostics.
EMV Capital
Acquisition in 2020
EMV Capital Ltd is a venture capital firm founded in 2018 and based in London, United Kingdom. The firm specializes in early-stage, high-growth deep tech companies, focusing on sectors such as life sciences, sustainability, and industrials. EMV Capital is dedicated to incubating and investing in companies at various stages, including seed, pre-Series A, Series A, and growth phases, while avoiding investments in apps, digital media, B2C companies, and unproven technologies. The firm seeks opportunities in healthcare, energy, transport, the circular economy, smart cities, robotics, AI, and other advanced technology sectors, primarily targeting businesses in the UK, US, and Israel. EMV Capital employs unique investment strategies tailored to each portfolio company, leveraging its extensive network of private investors and institutions to facilitate funding and drive transformational growth. It operates as a wholly owned subsidiary of NetScientific plc.
ProAxsis
Seed Round in 2014
ProAxsis Ltd. is a biotechnology company that focuses on developing laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers associated with various diseases. The company's innovative tests utilize patented ProteaseTags®, which are designed to trap active proteases within complex biological samples, allowing for a visual readout of their presence. ProAxsis has validated several active protease species as biomarkers of disease activity in conditions such as cancer, infections, and respiratory diseases, including bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). In 2016, the company registered its first immunoassay for the specific measurement of active neutrophil elastase, a significant biomarker for lung infection and inflammation, with a European CE Mark, highlighting its commitment to advancing medical diagnostics.
Nuada
Seed Round in 2012
Nuada is a vertically integrated company specializing in carbon capture technology aimed at decarbonizing heavy industries. The firm develops next-generation point-source capture solutions designed to facilitate energy-efficient CO2 filtration for industrial emitters in sectors that are difficult to decarbonize. By offering innovative technologies, Nuada enables these industries to meet their Net Zero targets while minimizing financial impacts. The company is committed to providing effective environmental solutions that address the challenges of carbon emissions in various industrial applications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.